Neurogene Inc. (ticker: NGNE) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of NGNE's SEC filings surfaces 3 active risk signals, including 2 auditor-change signals, and 1 late-filing signal. NGNE reported $0 in revenue and -$30.93M for the period ending 2025-12-31, with operating cash flow of -$26.12M. Cash and equivalents stood at $124.16M (up 75.4% year-over-year). Total assets of $263.14M exceed total liabilities of $25.36M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
NGNE Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Neurogene Inc. (NGNE) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.